Neumora Therapeutics Inc (NASDAQ: NMRA) is -81.79% lower on its value in year-to-date trading and has touched a low of $1.83 and a high of $21.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NMRA stock was last observed hovering at around $1.92 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $1.93, the stock is -10.46% and -72.58% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.72 million and changing 0.52% at the moment leaves the stock -81.23% off its SMA200. NMRA registered -87.85% loss for a year compared to 6-month loss of -84.99%. The firm has a 50-day simple moving average (SMA 50) of $7.0377 and a 200-day simple moving average (SMA200) of $10.283875.
The stock witnessed a -82.55% gain in the last 1 month and extending the period to 3 months gives it a -83.55%, and is -8.96% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.38% over the week and 10.59% over the month.
Neumora Therapeutics Inc (NMRA) has around 124 employees, a market worth around $311.81M and $0.00M in sales. Distance from 52-week low is 5.46% and -90.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-91.57%).
The EPS is expected to grow by 55.94% this year.
Neumora Therapeutics Inc (NMRA) Top Institutional Holders
154.0 institutions hold shares in Neumora Therapeutics Inc (NMRA), with institutional investors hold 91.47% of the company’s shares. The shares outstanding are 160.48M, and float is at 55.17M with Short Float at 19.99%. Institutions hold 66.34% of the Float.
Neumora Therapeutics Inc (NMRA) Insider Activity
The most recent transaction is an insider sale by Fust Matthew K, the company’s Director. SEC filings show that Fust Matthew K sold 14,049 shares of the company’s common stock on Oct 18 ’24 at a price of $17.03 per share for a total of $0.24 million. Following the sale, the insider now owns 20100.0 shares.
Neumora Therapeutics Inc disclosed in a document filed with the SEC on Oct 17 ’24 that Fust Matthew K (Director) sold a total of 7,739 shares of the company’s common stock. The trade occurred on Oct 17 ’24 and was made at $17.01 per share for $0.13 million. Following the transaction, the insider now directly holds 20100.0 shares of the NMRA stock.
Still, SEC filings show that on Oct 18 ’24, Fust Matthew K (Director) Proposed Sale 14,049 shares at an average price of $17.03 for $0.24 million. The insider now directly holds shares of Neumora Therapeutics Inc (NMRA).
